drugset / Trial / NCT03040635

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants

NCT03040635

Phase 1 Completed 24 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of Risdiplam in healthy Japanese participants.

Timeline

Start
2017-03-22
Primary completion
2017-10-02
Completion
2017-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Risdiplam Small molecule 2 mg Oral
Subject Risdiplam Small molecule 6 mg Oral
Subject Risdiplam Small molecule 12 mg Oral

Indications

No indication recorded.